Vicplas International (SGX:569), a medical devices and pipes manufacturer, expects to record a consolidated loss after tax of less than SG$1.8 million for the financial year ended July 31, 2024, reversing a S$4.2 million profit the previous year, according to a Tuesday filing on the Singapore Exchange.
The loss is being attributed to challenges in its medical devices segment, including lower sales as customers adjusted post-pandemic inventory levels, and higher costs linked to its Changzhou plant expansion and the startup of a new facility in Juarez, Mexico.
Despite this, the group's adjusted EBITDA is expected to remain positive, between SG$6.5 million and SG$7.5 million, compared to SG$14.7 million last year, supported by its pipes and pipe fittings segment.
Price (SGD): S$0.10, Change: S$+0.0010, Percent Change: +1.04%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。